

(3-methyl-TTNCB)
STANDARDIZED AGONIST DOSE RESPONSE




Fig. 1

(ALL TRANS RETINOIC ACID)
STANDARDIZED AGONIST DOSE RESPONSE




Fig. 2

RECEPTOR	
—	pRShRAR-alpha (wt)
—	pRShRAR-beta (wt)
—	pRShRAR-gamma (wt)
—	pRShRXR-alpha (wt)
—	pRSmRXR-beta (wt)
—	pRSmRXR-gamma (wt)

(9CIS RETINOIC ACID)
STANDARDIZED AGONIST DOSE RESPONSE




Fig. 3

(3-methyl-TTNEB)
STANDARDIZED AGONIST DOSE RESPONSE





Fig. 4



(3-bromo-TTNEB)
STANDARDIZED AGONIST DOSE RESPONSE





Fig. 5



(3-methyl-TTNCHBP)
STANDARDIZED AGONIST DOSE RESPONSE





Fig. 6



(3-methyl-TTNEHBP)
STANDARDIZED AGONIST DOSE RESPONSE





Fig. 7






Fig. 8




Fig. 9

EFFECT OF RETINOIDS ON RAT HDL CHOLESTEROL




Figure 10




Figure 11

Myeloma RPMI-8226 Cell Proliferation




Figure 12